Skip to main content

Seres Therapeutics, Inc. (MCRB)

NASDAQ: MCRB · Delayed Price · USD
7.06
+0.04 (0.57%)
After-hours:Sep 22, 2021 7:01 PM EDT
7.02
0.11 (1.59%)
At close: Sep 22, 4:00 PM
Market Cap633.78M
Revenue (ttm)29.96M
Net Income (ttm)-132.33M
Shares Out91.66M
EPS (ttm)-1.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,438,351
Open6.94
Previous Close6.91
Day's Range6.87 - 7.14
52-Week Range5.41 - 38.50
Beta3.96
AnalystsBuy
Price Target23.00 (+227.6%)
Est. Earnings DateNov 2, 2021

About MCRB

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use wit...

IndustryBiotechnology
IPO DateJun 26, 2015
CEOEric Shaff
Employees155
Stock ExchangeNASDAQ
Ticker SymbolMCRB
Full Company Profile

Financial Performance

In 2020, MCRB's revenue was $33.22 million, a decrease of -3.74% compared to the previous year's $34.51 million. Losses were -$89.13 million, 26.8% more than in 2019.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for MCRB stock is "Buy." The 12-month stock price forecast is 23.00, which is an increase of 227.64% from the latest price.

Price Target
$23.00
(227.64% upside)
Analyst Consensus: Buy

News

Why Seres Therapeutics Stock Is Soaring Today

The company completed its target enrollment in a pivotal clinical study.

1 week ago - The Motley Fool

Why Seres Therapeutics Shares Are Trading Higher Today

Seres Therapeutics (NASDAQ:MCRB) shares are trading higher after the company achieved enrollment of 300 subjects in its Phase 3 ECOSPOR IV study of SER-109. Seres Therapeutics' stock has been rising Wed...

1 week ago - Benzinga

Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109,...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has achieved enrollment of 300 subjects with the ECOSPOR IV open...

1 week ago - Business Wire

Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in three upcoming investor confere...

2 weeks ago - Business Wire

Seres Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres The...

1 month ago - Business Wire

Seres Therapeutics (MCRB) Reports Q2 Loss, Tops Revenue Estimates

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -29.27% and 19.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Recap: Seres Therapeutics Q2 Earnings

Shares of Seres Therapeutics (NASDAQ:MCRB) moved higher by 2.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 89.29% year over year to ($0.53), w...

1 month ago - Benzinga

Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company developing a novel class of multifunctional bacterial therapeutics designed to functionally inter...

1 month ago - Business Wire

Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast...

1 month ago - Business Wire

Why Seres Therapeutics Stock Is Crashing Today

The company reported disappointing results from a phase 2b clinical study.

2 months ago - The Motley Fool

Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to T...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast ...

2 months ago - Business Wire

Seres Therapeutics Stock Plunges As Ulcerative Colitis Candidate Disappoints In Mid-Stage Study

Seres Therapeutics Inc (NASDAQ: MCRB) has announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC).  The study did not mee...

2 months ago - Benzinga

Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced topline results from the Phase 2b ECO-RESET study evaluating SER-28...

2 months ago - Business Wire

Analysts Estimate Seres Therapeutics (MCRB) to Report a Decline in Earnings: What to Look Out for

Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Implied Volatility Surging for Seres Therapeutics (MCRB) Stock Options

Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Nestlé Bets $525M On Seres Therapeutics Microbiome Drug For Infectious Diseases

Seres Therapeutics Inc (NASDAQ: MCRB) has inked a $525-million deal with Nestlé Health Science to commercialize SER-109 if it can win FDA approval. SER-109 is an oral, live microbiome therapy under deve...

2 months ago - Benzinga

Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement

CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it has entered into an agreement with ...

2 months ago - Business Wire

Seres Therapeutics to Host Virtual Investor Event on June 21, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will host a virtual investor event focused on SER-287 and SER-301, potential new therapeutic options fo...

3 months ago - Business Wire

Seres Therapeutics to Present at JMP Securities Life Sciences Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Terri Young, Ph.D., R.Ph., Chief Commercial and Strategy Offi...

3 months ago - Business Wire

Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 Americ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from their collaboration with the University of Cologne (Köln,...

3 months ago - Business Wire

Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials

The FDA has signed off  Seres Therapeutics Inc's (NASDAQ: MCRB) Investigational New Drug (IND) application for SER-155 to initiate Phase 1 trial. SER-155 is a cultivated microbiome therapeutic designed ...

3 months ago - Benzinga

Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prev...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the U.S. Food and Drug Administration (FDA) has indicated studies for SER...

3 months ago - Business Wire

Seres Therapeutics to Present at Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will present a corporate overview at two upcoming ...

3 months ago - Business Wire

Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of its final 24-week data from the pivotal Phase 3 ECOSP...

4 months ago - Business Wire

Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that David Arkowitz will join as Executive Vice President, Chief Financial Officer (CFO) and Head of Business D...

4 months ago - Business Wire